SCHEMBL5539713

SCHEMBL5539713

[O]c1ccc2ccc(=O)oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 10/20 0.61
CA9 Q16790 10/20 0.61
CA1 P00915 7/20 0.61
KDM4E B2RXH2 6/20 0.61
MCL1 Q07820 5/20 0.61
ALDH1A1 P00352 5/20 0.61
GLA P06280 5/20 0.61
HSD17B10 Q99714 4/20 0.61
GAA P10253 4/20 0.61
AKR1B1 P15121 3/20 0.61
HPGD P15428 3/20 0.61
TDP1 Q9NUW8 3/20 0.61
CASP1 P29466 2/20 0.61
CASP7 P55210 2/20 0.61
ERAP1 Q9NZ08 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
CA4 P22748 5/20 0.56
CA7 P43166 5/20 0.56
CA14 Q9ULX7 5/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542275 0.84 CA12 (0.62) CA12CA9CA1KDM4EMCL1
SCHEMBL28330082 0.81 CA12 (0.53) CA12CA9CA1KDM4EMCL1
Umbelliferone SCHEMBL29396070 0.76 CA9 (1.00) CA12CA9CA1KDM4EMCL1
Umbelliferone SCHEMBL29624448 0.76 CA9 (1.00) CA12CA9CA1KDM4EMCL1
SCHEMBL30417141 0.76 PGR (0.59) CA12CA9CA1KDM4EMCL1
SCHEMBL646703 0.76 PGR (0.59) CA12CA9CA1KDM4EMCL1
SCHEMBL5040810 0.76 CA12 (0.59) CA12CA9CA1KDM4EMCL1
SCHEMBL31331748 0.76 CA12 (0.59) CA12CA9CA1KDM4EMCL1
SCHEMBL7919707 0.76 CA12 (0.59) CA12CA9CA1KDM4EMCL1
SCHEMBL11033273 0.76 CA12 (0.59) CA12CA9CA1KDM4EMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA12 1998/4885CA9 3134/4885CA1 3493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.